Arrowhead Pharmaceuticals, Inc. (ARWR) Analysts See $-0.13 EPS

December 12, 2017 - By Henry Gaston

 Arrowhead Pharmaceuticals, Inc. (ARWR) Analysts See $ 0.13 EPS

Analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report $-0.13 EPS on December, 13.They anticipate $0.18 EPS change or 58.06 % from last quarter’s $-0.31 EPS. After having $-0.07 EPS previously, Arrowhead Pharmaceuticals, Inc.’s analysts see 85.71 % EPS growth. The stock increased 1.74% or $0.06 during the last trading session, reaching $3.51. About 939,491 shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since December 12, 2016 and is downtrending. It has underperformed by 83.97% the S&P500.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 6 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Arrowhead Research Corp has $20.0 highest and $2.0 lowest target. $2.88’s average target is -17.95% below currents $3.51 stock price. Arrowhead Research Corp had 18 analyst reports since August 5, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained the shares of ARWR in report on Monday, September 25 with “Hold” rating. As per Monday, November 27, the company rating was upgraded by PiperJaffray. On Thursday, November 10 the stock rating was maintained by Chardan Capital Markets with “Buy”. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Neutral” rating given on Wednesday, November 30 by PiperJaffray. On Wednesday, November 30 the stock rating was downgraded by William Blair to “Mkt Perform”. Cantor Fitzgerald downgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Wednesday, November 30 to “Hold” rating. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, August 5 report. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Buy” rating given on Friday, August 19 by Cantor Fitzgerald. As per Monday, September 18, the company rating was upgraded by William Blair. As per Wednesday, November 30, the company rating was downgraded by Chardan Capital Markets.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $262.45 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

More recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Reuters.com which released: “BRIEF-Silence Therapeutics Says Sold Further Part Of Holding In Arrowhead …” on December 11, 2017. Also Businesswire.com published the news titled: “Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response …” on December 06, 2017. Businesswire.com‘s news article titled: “Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results” with publication date: December 05, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.